Amphastar Pharmaceuticals 

$20.91
284
+$0.73+3.62% Friday 20:00
+$0.00+0%Friday 20:15After hours

Statistics

Day High
21.07
Day Low
20
52W High
31.26
52W Low
16.65
Volume
299,883
Avg. Volume
568,651
Mkt Cap
921.98M
P/E Ratio
11.28
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.42
0.59
0.77
0.94
Expected EPS
0.851429
Actual EPS
N/A

Financials

13.63%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
719.89MRevenue
98.09MNet Income

Analyst Ratings

20.40Average Price Target
The highest estimate is 22.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
83%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Show more...
CEO
Dr. Ziping Luo Ph.D.
Employees
2028
Country
United States
ISIN
US03209R1032
WKN
000A11664

Listings

0 Comments

Share your thoughts

FAQ

What is Amphastar Pharmaceuticals stock price today?
The current price of AMPH is $20.91 USD — it has increased by +3.62% in the past 24 hours. Watch Amphastar Pharmaceuticals stock price performance more closely on the chart.
What is Amphastar Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Amphastar Pharmaceuticals stocks are traded under the ticker AMPH.
Is Amphastar Pharmaceuticals stock price growing?
AMPH stock has risen by +0.63% compared to the previous week, the month change is a +7.78% rise, over the last year Amphastar Pharmaceuticals has showed a -29.9% decrease.
What is Amphastar Pharmaceuticals market cap?
Today Amphastar Pharmaceuticals has the market capitalization of 921.98M
When is the next Amphastar Pharmaceuticals earnings date?
Amphastar Pharmaceuticals is going to release the next earnings report on November 09, 2026.
What were Amphastar Pharmaceuticals earnings last quarter?
AMPH earnings for the last quarter are 0.91 USD per share, whereas the estimation was 0.62 USD resulting in a +46.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amphastar Pharmaceuticals revenue for the last year?
Amphastar Pharmaceuticals revenue for the last year amounts to 719.89M USD.
What is Amphastar Pharmaceuticals net income for the last year?
AMPH net income for the last year is 98.09M USD.
How many employees does Amphastar Pharmaceuticals have?
As of August 15, 2026, the company has 2,028 employees.
In which sector is Amphastar Pharmaceuticals located?
Amphastar Pharmaceuticals operates in the Health & Wellness sector.
When did Amphastar Pharmaceuticals complete a stock split?
Amphastar Pharmaceuticals has not had any recent stock splits.
Where is Amphastar Pharmaceuticals headquartered?
Amphastar Pharmaceuticals is headquartered in Rancho Cucamonga, United States.